Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

Impact · against what's priced in

Silence Therapeutics sees a significant positive catalyst as divesiran meets its Phase II primary endpoint with high efficacy (88% response rate) and a strong safety profile. The results establish a clear regulatory path toward a Phase III registration trial in early 2027 with a competitive quarterly dosing regimen.

SLN+0.80

No priced-in read yet

In context

The Phase II SANRECO trial demonstrated that 88% of treated patients maintained hematocrit below 45% without phlebotomy compared to 18% for placebo (p < 0.0001). The absence of new safety issues and the plan to advance a quarterly dosing regimen into Phase III significantly de-risk the core asset.

Read from the article alone

• biotech▲22%
• SLN
• clinical trial
• fda
• hematology
• phase ii
• phase iii
• polycythemia vera
• rare disease
• rnai